YahooSeptember 28, 2026 at 11:10 AM NY29 Days Ago
MediciNova Drug Falls Short on Liver Fat Parameter, Stock Tumbles
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus. The exploratory study highlighted improvements in cardiovascular lipid markers, alongside positive trends in liver fat reduction and body weight loss. Phase 2 Trial Design And Efficacy Findings The MN-001-NATG-202
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
